Alere Inc (NYSE:ALR) has been given a consensus rating of “Hold” by the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $48.00.

A number of equities analysts have recently weighed in on the company. BidaskClub downgraded Alere from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Alere from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Finally, Canaccord Genuity restated a “hold” rating and issued a $51.00 target price on shares of Alere in a research note on Tuesday, September 19th.

Several hedge funds and other institutional investors have recently made changes to their positions in ALR. Bank of New York Mellon Corp boosted its stake in shares of Alere by 0.7% in the 1st quarter. Bank of New York Mellon Corp now owns 391,002 shares of the medical research company’s stock worth $15,535,000 after buying an additional 2,583 shares during the last quarter. UBS Asset Management Americas Inc. raised its holdings in shares of Alere by 23.4% in the 1st quarter. UBS Asset Management Americas Inc. now owns 65,964 shares of the medical research company’s stock worth $2,621,000 after purchasing an additional 12,521 shares during the period. Karp Capital Management Corp bought a new stake in shares of Alere in the 1st quarter worth approximately $472,000. Parametric Portfolio Associates LLC raised its holdings in shares of Alere by 7.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 85,861 shares of the medical research company’s stock worth $3,411,000 after purchasing an additional 6,002 shares during the period. Finally, Asset Management One Co. Ltd. raised its holdings in shares of Alere by 0.5% in the 1st quarter. Asset Management One Co. Ltd. now owns 15,940 shares of the medical research company’s stock worth $633,000 after purchasing an additional 79 shares during the period. Hedge funds and other institutional investors own 89.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/17/alere-inc-alr-receives-average-recommendation-of-hold-from-brokerages.html.

Alere Company Profile

Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

Analyst Recommendations for Alere (NYSE:ALR)

Receive News & Stock Ratings for Alere Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc and related stocks with our FREE daily email newsletter.